Sophia Genetics Sa - SOPH STOCK NEWS

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company specializing in data-driven medicine, has scheduled its fourth quarter and full year 2024 financial results announcement for March 4, 2025, before U.S. markets open. The company will host a conference call at 8:00 a.m. EDT / 2:00 p.m. CET to discuss the financial results and business outlook. The call will be available via webcast on the SOPHiA GENETICS Investor Relations Website, with a replay option provided after the event.

SOPHiA GENETICS (SOPH) has launched the OncoPortal™ Mutation Tracker, a new longitudinal MRD tracking tool for oncology disease monitoring. This add-on module for the SOPHiA DDM™ Platform enables tracking of genomic variants across multiple time points in cancer patients.

The tool combines longitudinal tracking capabilities with next-generation sequencing (NGS) to detect cancer-specific genetic mutations at very low frequencies. Key features include flexible low frequency variant selection, customizable threshold settings, and reporting features that generate longitudinal graphical representations.

According to Dr. Philippe Menu, Chief Medical Officer, the ability to track low frequency variants longitudinally is revolutionary as it enables detection of minimal cancer traces that might escape traditional testing methods. Dr. Christophe Marzac from Gustave Roussy Institute praised the interface as a important solution for broader NGS adoption among oncologists.

SOPHiA GENETICS (SOPH) has globally launched MSK-IMPACT® powered with SOPHiA DDM™, a comprehensive genomic profiling application developed in collaboration with Memorial Sloan Kettering Cancer Center. The solution enables organizations worldwide to access advanced tumor profiling technologies with high accuracy and efficiency. The platform demonstrates exceptional performance with 99.3% positive agreement for SNV/Indel detection and 94.6% for CNV detection. SOFIVA GENOMICS in Taiwan is among the first adopters, expanding their tumor profiling capabilities. The workflow takes approximately five days from DNA extraction to final report, integrating OncoKB™ for enhanced analytical insights.

SOPHiA GENETICS (Nasdaq: SOPH) has announced key leadership changes effective November 5, 2024. Ross Muken, previously CFO and COO, has been promoted to company President, where he will oversee global business operations and strategic planning alongside CEO Jurgi Camblong. George Cardoza joins as the new CFO, bringing over 30 years of experience in precision medicine and clinical diagnostics. Cardoza, who previously served as CFO at Biocartis and held executive roles at NeoGenomics Laboratories and Quest Diagnostics, will oversee all corporate finance functions including accounting, FP&A, investor relations, internal audit, tax, and treasury.

SOPHiA GENETICS (SOPH) reported Q3 2024 financial results with revenue of $15.9 million, down 2.8% year-over-year. The company achieved gross margins of 67.2% (reported) and 73.1% (adjusted). Operating loss improved to $15.4 million (reported) and $10.6 million (adjusted), showing improvements of 7.1% and 10.4% respectively. Cash burn decreased significantly by 39.1% to $9.6 million. Clinical analysis volume grew 16% year-over-year, despite BioPharma softness. The company maintains its full-year guidance of $65-67 million in revenue, 72.0-72.5% adjusted gross margin, and adjusted operating loss between $45-50 million.

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company specializing in data-driven medicine, has announced the release date for its third quarter 2024 financial results. The company will disclose its financial performance before U.S. markets open on Tuesday, November 5, 2024. Following the release, SOPHiA GENETICS will host a conference call at 8:00 a.m. EDT / 2:00 p.m. CET to discuss the financial results and provide a business outlook. Investors and interested parties can access the webcast live on the SOPHiA GENETICS Investor Relations Website. For those unable to attend the live call, a replay will be made available on the company's website after the event's conclusion.

SOPHiA GENETICS (Nasdaq: SOPH) will present groundbreaking research at ESMO 2024, showcasing AI-driven patient stratification for non-small cell lung cancer (NSCLC) treatment. The study, conducted with AstraZeneca, analyzed the POSEIDON Phase 3 clinical trial using multimodal machine learning to identify NSCLC patient subgroups most likely to benefit from combination immunotherapy.

The research revealed signatures associated with higher overall survival benefit from adding tremelimumab to durvalumab and chemotherapy in first-line treatment of metastatic NSCLC. Key genetic factors included EGFR wild-type, FGFR3 wild-type, CDKN2A wild-type, KRAS mutation, and STK11 mutation. This approach could significantly impact NSCLC treatment by enabling more personalized care strategies.

SOPHiA GENETICS (Nasdaq: SOPH) will present two posters at the ESMO Congress 2024 in Barcelona. The first poster focuses on the analytical validation of an NGS panel-based ecDNA detection device for Boundless Bio's POTENTIATE clinical study. This innovative tool aims to detect extrachromosomal DNA in cancer patients, potentially improving patient selection for clinical trials.

The second poster presents the TRIDENT study, which uses machine learning to develop multimodal signatures for identifying patients who would benefit most from adding tremelimumab to durvalumab and chemotherapy in first-line treatment of stage IV non-small cell lung cancer. This study is based on a retrospective analysis of the POSEIDON Phase 3 trial.

SOPHiA GENETICS (Nasdaq: SOPH) announced updates on SOPHiA UNITY, its global consortium for precision oncology research, at ESMO 2024. Several world-renowned healthcare organizations have joined the initiative, including Exactis Innovation in Canada, Institut Paoli-Calmettes in France, and potentially Gemelli Hospital in Italy. These institutions join inaugural member Memorial Sloan Kettering Cancer Center, expanding the network to three countries and over 100,000 committed patient profiles with multimodal data.

SOPHiA UNITY aims to accelerate oncology innovation by harmonizing high-quality, diverse data at scale. Members benefit from participating in industry-funded global projects and access to SOPHiA GENETICS' AI-driven technology for efficient data curation and harmonization. The initiative leverages SOPHiA CarePath™, which provides insights from various data modalities including imaging, genomics, pathology, and clinical notes.